Suchergebnisse - "Perrone, Francesco"

PubPharm (403)

81

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer : HOBOE phase 3 randomised trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Perrone, F. | De Laurentiis, M. | De Placido, S. | +29

CommentIn: Eur J Cancer. 2019 Sep;118:166-168. - PMID 31374402

82

Assessing Financial Toxicity in Patients With Cancer : Moving Away From a One-Size-Fits-All Approach

enthalten in: Journal of oncology practice | 2019

von Perrone, F. | Di Maio, M. | Efficace, F. | +4

CommentOn: J Oncol Pract. 2019 Apr;15(4):e300-e307. - PMID 30844331

83

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

enthalten in: Gynecologic oncology | 2019

von Daniele, G. | Arenare, L. | Scambia, G. | +25

84

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer : Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Morabito, A. | Piccirillo, M. | Maione, P. | +27

85

The MITO CERV-2 trial : A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

enthalten in: Gynecologic oncology | 2019

von Pignata, S. | Scambia, G. | Lorusso, D. | +29

86

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018

enthalten in: Journal of translational medicine | 2019

von Ascierto, P. | Bruzzi, P. | Eggermont, A. | +7

87

The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018

enthalten in: Journal of translational medicine | 2019

von Ascierto, P. | Bruzzi, P. | Eggermont, A. | +7

88

The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018

enthalten in: Journal of translational medicine | 2019

von Ascierto, P. | Bruzzi, P. | Eggermont, A. | +7

89

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

enthalten in: Cancers | 2019

von Rachiglio, A. | Fenizia, F. | Piccirillo, M. | +17

90

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology

enthalten in: PloS one | 2019

von Pascarella, G. | Capasso, A. | Nardone, A. | +17